^
    Back
    Association details:
    Biomarker:STK11 mutation + TP53 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Thorac Dis
    Title:

    Clinical outcomes and immune phenotypes associated with STK11 co-occurring mutations in non-small cell lung cancer

    Excerpt:
    Forty-one patients with STK11-mutated NSCLC seen in our Thoracic oncology clinic with available next-generation sequencing tumor data were included in the analysis….TP53 co-mutation was associated with improved clinical benefit with immunotherapy.
    DOI:
    10.21037/jtd-21-1377